Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 16/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15607072 | 0.83 | WNT3A (0.53) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1912339 | 0.81 | LOXL2 (0.56) | WNT3AMAP4K4 | |
| SCHEMBL18703785 | 0.80 | WNT3A (0.42) | WNT3AMAP4K4 | |
| SCHEMBL1912303 | 0.80 | DYRK1A (0.56) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492636 | 0.78 | MAP4K4 (0.50) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3423338 | 0.78 | CCR1 (0.56) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14355099 | 0.78 | CYP11B1 (0.57) | — | |
| SCHEMBL1912345 | 0.77 | LOXL2 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1912413 | 0.76 | WNT3A (0.52) | WNT3A | |
| SCHEMBL6673316 | 0.76 | AURKA (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101023-A1 | HETEROARYL DERIVATIVE AND USES THEREOF | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) (KR) | 2025-03-27 | — | — | US | disclosed |
| WO-2023140640-A1 | HETEROARYL DERIVATIVE AND USES THEREOF | 한양대학교 산학협력단 | 2023-07-27 | — | — | WO | disclosed |
| US-20220281873-A1 | COMPOUND AS PORCUPINE INHIBITOR AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2022-09-08 | — | — | US | disclosed |
| US-20210054466-A1 | TUMOR BIOMARKERS AND USE THEREOF | CUREGENIX CORPORATION | 2021-02-25 | — | — | US | disclosed |
| US-20210054466-A1 | TUMOR BIOMARKERS AND USE THEREOF | CUREGENIX CORPORATION | 2021-02-25 | — | — | US | disclosed |
| US-10660889-B2 | Compounds for treatment of cancer | CUREGENIX, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-10660889-B2 | Compounds for treatment of cancer | CUREGENIX, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-20190209558-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | CUREGENIX, INC. (CN) | 2019-07-11 | — | — | US | disclosed |
| US-20190209558-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | CUREGENIX, INC. (CN) | 2019-07-11 | — | — | US | disclosed |
| US-20190142827-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CUREGENIX, INC. (CN) | 2019-05-16 | — | — | US | disclosed |
| WO-2014165232-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CUREGENIX, INC. (CN) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165232-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CUREGENIX, INC. (CN) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014159733-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | CUREGENIX, INC. (CN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159733-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | CUREGENIX, INC. (CN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013185353-A1 | COMPOUND AS WNT SIGNALING INHIBITOR, COMPOSITION, AND USE THEREOF | CUREGENIX INC. (CN) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013185353-A1 | COMPOUND AS WNT SIGNALING INHIBITOR, COMPOSITION, AND USE THEREOF | CUREGENIX INC. (CN) | 2013-12-19 | — | — | WO | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| WO-2012088712-A1 | COMPOUND AS WNT SIGNALING INHIBITOR, COMPOSITION, AND USE THEREOF | CUREGENIX INC. (CN) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012003189-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | IRM LLC (BM) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281873-A1 | COMPOUND AS PORCUPINE INHIBITOR AND USE THEREOF | PORCN, SLC6A1, SLC6A11 | WNT3A 1322/4885PSEN1 45/4885PSEN2 53/4885 |
| US-20250101023-A1 | HETEROARYL DERIVATIVE AND USES THEREOF | ERBB2, ERBB3, FGFR2 | WNT3A 253/4885PSEN1 4528/4885PSEN2 2839/4885 |
| US-20190209558-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | WNT1, SFRP1, WNT3 | WNT3A 6/4885PSEN1 2784/4885PSEN2 2741/4885 |
| US-10660889-B2 | Compounds for treatment of cancer | WNT1, CTNNB1, WNT3 | WNT3A 5/4885PSEN1 3251/4885PSEN2 3276/4885 |
| US-20190142827-A1 | COMPOUNDS FOR TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | WNT3A 5/4885PSEN1 3251/4885PSEN2 3276/4885 |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | WNT3A 1/4885PSEN1 3229/4885PSEN2 2760/4885 |
| US-20210054466-A1 | TUMOR BIOMARKERS AND USE THEREOF | CTNNB1, CTNNBL1, WNT1 | WNT3A 9/4885PSEN1 2603/4885PSEN2 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.